uniQure NV QURE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
UniQure's Fabry Disease Treatment Gets Orphan Drug Designation from FDA
-
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
-
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
-
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
-
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
-
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
-
UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease
-
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul
Trading Information
- Previous Close Price
- $4.56
- Day Range
- $4.82–5.72
- 52-Week Range
- $3.73–11.35
- Bid/Ask
- $5.66 / $5.69
- Market Cap
- $275.14 Mil
- Volume/Avg
- 2.1 Mil / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 480
- Website
- https://www.uniqure.com
Comparables
Valuation
|
Metric
|
QURE
|
PHARM
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 15.15 |
Price/Book Value | 2.83 | 2.40 | 2.78 |
Price/Sales | 9.82 | 2.15 | 6.69 |
Price/Cash Flow | — | 92.38 | 14.35 |
Price/Earnings
QURE
PHARM
UTHR
Financial Strength
|
Metric
|
QURE
|
PHARM
|
UTHR
|
|---|---|---|---|
Quick Ratio | 6.61 | 2.65 | 3.92 |
Current Ratio | 7.36 | 3.39 | 4.35 |
Interest Coverage | −3.84 | −2.21 | 22.67 |
Quick Ratio
QURE
PHARM
UTHR
Profitability
|
Metric
|
QURE
|
PHARM
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −31.33% | −4.16% | 16.95% |
Return on Equity (Normalized) | −121.03% | −8.62% | 20.53% |
Return on Invested Capital (Normalized) | −66.72% | −4.69% | 16.62% |
Return on Assets
QURE
PHARM
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vxrqhbcxyf | Zssbk | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nlbhztkx | Qynxljv | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mfxxmxnh | Lrgxyn | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qnpswkqf | Zbfprd | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Pjpwzms | Jrhxj | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Vrhmtkmkt | Hjjw | $29.2 Bil | |||
| Moderna Inc
MRNA
| Lxvjkfrv | Tpqtc | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tcjrqry | Xlxz | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pjkkcvz | Mzlpcsm | $13.2 Bil | |||
| Incyte Corp
INCY
| Zctwzkrh | Ypgzfzy | $13.0 Bil |
United States